DJIA 16,982.59 22.02 0.13%
NASDAQ 4,444.91 -4.66 -0.10%
S&P 500 1,978.91 0.57 0.03%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

Pre-Market Earnings Report for May 1, 2014 : XOM, COP, MA, EPD, TEVA, MFC, SHPG, AMT, VIAB, MPC, K,

Pre-Market Earnings Report for May 1, 2014 : XOM, COP, MA, EPD, TEVA, MFC, SHPG, AMT, VIAB, MPC, K, CAH

Teva Shares Flat After Company Reported Positive Results from Phase III Study to Evaluate Hydrocodon

Teva Shares Flat After Company Reported Positive Results from Phase III Study to Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237)

OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog

Is Actavis (ACT) Poised to Beat Earnings Estimates? - Analyst Blog

Is Actavis (ACT) Poised to Beat Earnings Estimates? - Analyst Blog

Momenta Pharmaceuticals Has Value In The Sum Of The Drugs

US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

Will Bristol-Myers (BMY) Beat Q1 Earnings? - Analyst Blog

Will Forest Labs (FRX) Keep Its Earnings Streak Alive? - Analyst Blog

Benzinga's Top #PreMarket Losers

UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase III SYNERGY Trial for Combo with Fi

UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase III SYNERGY Trial for Combo with First-Line Docetaxel, Prednisone, Primary End Point Was Not Reached